Elo Mutual Pension Insurance Co Increases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Elo Mutual Pension Insurance Co grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.3% during the fourth quarter, HoldingsChannel reports. The fund owned 18,860 shares of the medical research company’s stock after purchasing an additional 2,777 shares during the period. Elo Mutual Pension Insurance Co’s holdings in IQVIA were worth $3,706,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new position in IQVIA during the third quarter worth about $223,000. Algert Global LLC purchased a new stake in shares of IQVIA in the third quarter valued at about $514,000. Larson Financial Group LLC increased its stake in shares of IQVIA by 745.1% during the 3rd quarter. Larson Financial Group LLC now owns 431 shares of the medical research company’s stock worth $102,000 after purchasing an additional 380 shares in the last quarter. Fisher Asset Management LLC lifted its stake in IQVIA by 4.8% in the 3rd quarter. Fisher Asset Management LLC now owns 7,398 shares of the medical research company’s stock valued at $1,753,000 after buying an additional 341 shares in the last quarter. Finally, Private Trust Co. NA increased its position in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Morgan Stanley raised their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Price Performance

Shares of NYSE IQV opened at $177.27 on Friday. IQVIA Holdings Inc. has a 1-year low of $176.03 and a 1-year high of $253.84. The firm has a market capitalization of $31.25 billion, a PE ratio of 23.64, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business’s fifty day moving average price is $193.15 and its two-hundred day moving average price is $206.47.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.